Methodological Issues in Clinical Drug Development for Essential Tremor

  • Michael A. Carranza
  • Madeline R. Snyder
  • Rodger J. Elble
  • Angelique E. Boutzoukas
  • Theresa A. Zesiewicz


Essential tremor (ET) is one of the most common tremor disorders in the world. Despite this, only two medications have received Level A recommendations from the American Academy of Neurology to treat it (primidone and propranolol). Even though these medications provide relief to a large group of ET patients, up to 50% of patients are non-responders. Additional medications to treat ET are needed. This review discusses some of the methodological issues that should be addressed for quality clinical drug development in ET.